Lehigh Valley Health Network

LVHN Scholarly Works
Department of Medicine

Antiretroviral Therapy (ART) in Clinical Practice:
Effectiveness and Tolerability of Necvirapine
(NVP), Stavudine (d4T) and Lamivudine (3TC)
Joseph L. Yozviak DO, FACP
Lehigh Valley Health Network, joseph.yozviak@lvhn.org

R Eric Doerfler NP, CCH
Bornemann Internal Medicine

William C. Woodward DO
Bornemann Internal Medicine

Follow this and additional works at: http://scholarlyworks.lvhn.org/medicine
Part of the Chemicals and Drugs Commons, Diseases Commons, Infectious Disease Commons,
and the Medical Sciences Commons
Published In/Presented At
Yozviak, J., Doerfler, R., & Woodward, W. (2000, September 17-20). Antiretroviral therapy (ART) in clinical practice: effectiveness and
tolerability of nevirapine (NVP), stavudine (d4T) and lamivudine (3TC). Poster presented at: The 40th Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Ontario, Canda.

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an
authorized administrator. For more information, please contact LibraryServices@lvhn.org.

7239 Vir. Woodward (ART)

9/7/00

5:53 PM

Page 1

40th ICAAC
September 17-20, 2000
Toronto, Canada
Abstract 1519

Jody L. Yozviak
Philadelphia College of Osteopathic Medicine
Philadelphia, PA
E-mail: joyoz@erols.com

ANTIRETROVIRAL THERAPY (ART) IN CLINICAL PRACTICE: EFFECTIVENESS AND TOLERABILITY OF
NEVIRAPINE (NVP), STAVUDINE (d4T), AND LAMIVUDINE (3TC)
J. L. Yozviak,1 R. E. Doerfler,2 and W. C. Woodward2*
Philadelphia College of Osteopathic Medicine, Philadelphia, PA, USA, 2Bornemann Internal Medicine, Reading, PA, USA

1

ABSTRACT

METHODS

Background: Recent studies reveal that viral suppression in clinical
practice is achieved less frequently than in clinical trials. This study
examines the effectiveness and tolerability of an NVP/d4T/3TC ART
regimen in an urban HIV clinical practice. Methods: A retrospective
review of patients (N = 536) from 9/96 to 4/00 yielded 73 patients
on NVP/d4T/3TC. Abstracted data: demographics, viral load (VL), CD4+,
previous regimen, and adverse events (AE). VL was evaluated by
percentage of patients <400 copies/mL by week 16 and <50 copies/mL
by week 24. Other studies have suggested that this predicts long-term
durability. Analyses performed: intent-to-treat (ITT) (prescription
written), and as-treated (AT). Results: Study patients were similar to
practice demographics; 12/73 (16.4%) were ART-naive. Common
reasons for choosing NVP/d4T/3TC: low baseline VL (BLVL), avoidance
of PI-associated AEs, and fewer pills/doses. ITT: Week 16: 57/73
(78.1%) had VL <400. Week 24: 33/73 (45.2%) had VL <50. AT:
Week 16: 66 patients had follow-up data; 57/66 (86.4%) had VL
<400. Week 24: 39 patients had ultrasensitive results; 33/39 (84.6%)
had VL <50. Beyond 48 weeks: 13/14 (92.9%) were <50. Mean CD4+
increase was 170 (95% CI: 122, 218). Discontinuations (d/c): 4/73
(5.5%) due to rash, 10/73 (13.7%) due to other AEs, 19/73 (26.0%)
for other reasons (nonadherence, illicit drug use, STI), and 8/73
(11.0%) due to virologic failure; 4/8 reported nonadherence.
Conclusions: Despite a low genetic barrier, NVP/d4T/3TC is effective
and tolerable. Virologic success was higher than expected in an
urban clinic. There was a low incidence of d/c due to rash or virologic
failure. Most d/c were not ART-related. The low pill burden, ease
of administration, and lack of AEs make this regimen suitable and
effective in clinical practice.

• A retrospective chart review of all patients (N = 536) seen from
9/96 to 4/00 was conducted at Bornemann Internal Medicine
(BIM), an urban HIV clinic
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Other: headache, vertigo, fatigue, embarrassment, stress, depression, lost insurance, prison.
34 patients discontinued; 7 patients discontinued for more than one reason.

• The use of the NNRTI-based regimen of nevirapine, stavudine, and lamivudine resulted in virologic success rates

Week 24 results are based only on patients with ultrasensitive results.
P = 0.001. All other differences between the high and low BLVL subsets were not significant (P >0.05).
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• Intent-to-Treat (ITT) (prescription written, no data = failure) and
As-Treated (AT) analyses were performed. Patient questioning
and self-report determined noncompliance
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• Viral load response was evaluated by the percentage of patients
<400 copies/mL by 16 weeks and <50 copies/mL by 24 weeks,
for those with ultrasensitive (UQ) data. Other studies have suggested that this is predictive of long-term success.5,6 Patients
who discontinued the regimen due to AEs before the week of
analysis were considered failures for that time period

BACKGROUND
In clinical practice, patients on protease inhibitor (PI)-based regimens
achieve viral suppression less frequently than in randomized, doubleblinded, placebo-controlled, clinical trials.1,2,3 Many factors influence
this discrepancy, including adherence and the use of HAART in
heavily treatment-experienced patients. To avoid the complex dosing
schedules and side effects of PI therapy, the non-nucleoside reverse
transcriptase inhibitors (NNRTIs) have been utilized as an alternative
in patients with lower baseline viral loads (BLVL). Recent data suggest
that the potency of NNRTI-based regimens in patients with a BLVL
greater than 100,000 copies per mL plasma is sufficient to result in
long-term viral suppression.4 When this feature is combined with
simple dosing schedules and fewer side effects, the use of NNRTIs
can result in the design of highly efficacious, tolerable, and convenient (ETC) regimens. This study examines the ETC of nevirapine
(NVP), stavudine (d4T), and lamivudine (3TC) in patients in an
urban HIV practice.
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• Charts were abstracted for the following: demographics, viral
load (VL), CD4+ cell count, previous regimen, adverse events
(AEs), and reasons for discontinuation

Sex:

Table 4. Reasons for discontinuation

Figure 1. Plasma HIV-1 RNA <400 by week 16 and <50 by week 24†

Other: itching, diarrhea, constipation, vertigo, decreased appetite

similar to or better than what would be expected based on previous studies of other NVP-containing regimens 4,7
• Although the high BLVL group had a lower baseline CD4+ count (P = 0.003), virologic success rates were
similar to the low BLVL group. In fact, the only significant difference was a higher percentage of patients
in the high BLVL group who were <400 copies/mL at 16 weeks in the AT analysis (P = 0.001). The week
24 ITT results are deceptively low in each group due to a large number of patients (34) who did not have
ultrasensitive results available for analysis. Although only 14 patients had been taking the regimen for
>48 weeks (mean = 98.0 weeks) at the time of submission, the results suggest the potential for long-term
durability. No statistically significant differences in immunologic response were noted
• In our practice, patients choose the regimen that is most appropriate for their lifestyle after discussion of
all efficacious HAART options and the consequences of each. Most patients (53.4%) chose NVP/d4T/3TC
due to a low BLVL. However, the underlying logic was still the avoidance of PI-related AEs and complex
dosing since the “extra” potency of PIs was not indicated. The remaining patients chose the regimen
directly to avoid PI-based HAART. This suggests a patient preference for NVP-based HAART due to its
potential increased tolerability and convenience of dosing
• Although rash was the most common AE reported, the incidence was low (13.7%). Only 4 patients (5.5%)
discontinued the regimen due to severe NVP-related rash
• Most discontinuations were not due to AEs, but to external factors. Of those patients with virologic failure
(11.0%), 50% reported poor medication adherence. This reminds providers of the importance of adherence in
the execution of the treatment plan
• This result is in agreement with Raffi et al,4 suggesting that NVP/d4T/3TC has high potency regardless of BLVL
• In summary, NVP/d4T/3TC appears to be an effective, tolerable, and convenient regimen for both
treatment-naive and treatment-experienced patients regardless of BLVL. Additional prospective
examination of the use of NVP-based regimens in such patient groups is warranted
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